These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11926199)

  • 21. Lack of pharmacokinetic interaction between pantoprazole and diclofenac.
    Bliesath H; Huber R; Steinijans VW; Koch HJ; Wurst W; Mascher H
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S76-80. PubMed ID: 8793607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lansoprazole--a new acid pump inhibitor].
    Ejlersen E; Tage-Jensen U
    Ugeskr Laeger; 1995 May; 157(20):2871-3. PubMed ID: 7785109
    [No Abstract]   [Full Text] [Related]  

  • 23. Determination of pantoprazole in human plasma by LC-MS-MS using lansoprazole as internal standard.
    Peres O; Oliveira CH; Barrientos-Astigarraga RE; Rezende VM; Mendes GD; de Nucci G
    Arzneimittelforschung; 2004; 54(6):314-9. PubMed ID: 15281616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
    Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
    Uygun A; Kadayifçi A; Yeşilova Z; Savaş MC; Ateş Y; Karslioğlu Y; Ciğerim M; Bağci S; Dağalp K
    Turk J Gastroenterol; 2004 Dec; 15(4):219-24. PubMed ID: 16249974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
    Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
    Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
    Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):51-5. PubMed ID: 8929746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In treatment of active duodenal ulcer and Helicobacter pylori eradication.
    Yukselen V; Yasa MH; Karaoglu AO
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cccvi-cccviii. PubMed ID: 15244210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigations on the thermal behavior of omeprazole and other sulfoxides.
    Rosenblatt KM; Bunjes H; Seeling A; Oelschläger H
    Pharmazie; 2005 Jul; 60(7):503-7. PubMed ID: 16076075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients.
    Pilotto A; Leandro G; Franceschi M; Bierti L; Di Battista R; Notarbartolo A; Pisciotta G; Grassi A; Crestani B; Tafner G; Michelagnoli S; Garotta F
    Hepatogastroenterology; 1999; 46(25):245-51. PubMed ID: 10228801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
    Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
    Masubuchi N; Hakusui H; Okazaki O
    Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of pantoprazole drug interactions in man.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
    Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial-rate method for the determination of pantoprazole in pharmaceutical formulations using 1-fluoro 2,4-dinitrobenzene.
    Rahman N; Kashif M
    Pharmazie; 2005 Mar; 60(3):197-200. PubMed ID: 15801672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyl radical scavenging reactivity of proton pump inhibitors.
    Simon WA; Sturm E; Hartmann HJ; Weser U
    Biochem Pharmacol; 2006 Apr; 71(9):1337-41. PubMed ID: 16494850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.